Stockscreener 앱 받기
0.111
8.93%
0.0091
시간 외 거래:
.12
0.009
+8.11%
전일 마감가:
$0.1019
열려 있는:
$0.104
하루 거래량:
23.65M
Relative Volume:
8.58
시가총액:
$9.45M
수익:
-
순이익/손실:
$-37.28M
주가수익비율:
-0.1609
EPS:
-0.69
순현금흐름:
$-32.24M
1주 성능:
-76.09%
1개월 성능:
-80.59%
6개월 성능:
-85.20%
1년 성능:
-91.72%
1일 변동 폭
$0.1019
$0.1239
1주일 범위
$0.0862
$0.5053
52주 변동 폭
$0.0862
$2.57
Eyenovia Inc Stock (EYEN) Company Profile
명칭
Eyenovia Inc
전화
813-766-9539
주소
295 MADISON AVENUE,, NEW YORK, NY
EYEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| EYEN | 0.111 | 9.45M | 0 | -37.28M | -32.24M | -0.69 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-01 | 개시 | Northland Capital | Outperform |
| 2020-02-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
Eyenovia Inc 주식(EYEN)의 최신 뉴스
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study - Yahoo Finance Australia
Eyenovia stock downgraded to Neutral, price target set on challenges By Investing.com - Investing.com UK
Eyenovia stock plummets following Phase III myopia trial failure - Yahoo! Voices
Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study - Marketscreener.com
Eyenovia to Cut 50% of Workforce After Phase 3 Study Disappoints - MarketWatch
Eyenovia to end eye drug study, cut 50% of its workforce - Reuters
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline - AOL
Eyenovia Shares Plumb New Depths After Study Failure - MarketWatch
Eyenovia Shares Plummet 70% After It Drops Lead Program - BioSpace
Eyenovia plunges as late-stage trial for myopia treatment fails - MSN
Eyenovia stock plunges after trial setback (EYEN:NASDAQ) - Seeking Alpha
Eyenovia discontinues late-stage eye drug study, shares fall - XM
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Eyenovia Inc - GuruFocus.com
Eyenovia Mulls Options After Phase 3 Study Failure - MarketWatch
Eyenovia halts myopia study after missing primary endpoint - Investing.com
Eyenovia Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Eyenovia Provides Update on Phase 3 CHAPERONE Study - GlobeNewswire
Eyenovia's Phase 3 Myopia Drug Trial Fails Primary Endpoint, Company Weighs Options | EYEN Stock News - StockTitan
Brookline Capital Downgrades Eyenovia (EYEN) - MSN
Eyenovia, Inc. (NASDAQ:EYEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Eyenovia’s Strategic Advances and Q3 Financials - TipRanks
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Eyenovia Inc Reports Q3 2024 Earnings: EPS of -$0.11 Beats Estim - GuruFocus.com
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Eyenovia Reports Mixed Q3: New Drug Launch Amid Widening Losses; Cash Position at $7.2M | EYEN Stock News - StockTitan
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th - The Manila Times
EYEN (Eyenovia) Cash Flow from Operations : $-30.23 Mil (TTM As of Jun. 2024) - GuruFocus.com
Eyenovia reveals Optejet dispenser benefits in study - Investing.com
Eyenovia Announces Publication of Study Demonstrating - GlobeNewswire
Eyenovia reveals Optejet dispenser benefits in study By Investing.com - Investing.com UK
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet® - StockTitan
Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now - MSN
EYENEyenovia, Inc. Latest Stock News & Market Updates - StockTitan
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo - The Manila Times
Eyenovia Announces Presentation of Phase 3 Clobetasol Study - GlobeNewswire
Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Wall Street analysts’ outlook for Eyenovia Inc (EYEN) - SETE News
Monitoring Eyenovia Inc (EYEN) after recent insider movements - Knox Daily
Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Eyenovia Inc’s results are impressive - US Post News
Quarterly Snapshot: Quick and Current Ratios for Eyenovia Inc (EYEN) - The Dwinnex
Eyenovia Inc [EYEN] Records 200-Day SMA of $1.0954 - Knox Daily
Eyenovia begins manufacturing next-gen drug delivery system - Drug Delivery Business News
Top investors say Eyenovia Inc (EYEN) ticks everything they need - SETE News
Eyenovia begins Gen-2 Optejet production for Mydcombi By Investing.com - Investing.com South Africa
Eyenovia begins Gen-2 Optejet production for Mydcombi - Investing.com
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device - The Manila Times
Eyenovia Inc (EYEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):